Drug ID:Drug71
Drug Name:Rosuvastatin
CID:446157
DrugBank ID:DB01098
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT05912387, , NCT04883840
Molecular Formula:C22H28FN3O6S
Molecular Weight:481.5 g/mol
Isomeric SMILES:CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
Synonyms:Rosuvastatin; 287714-41-4; Creston; X-Plended; Rosuvastatina; ZD-4522; UNII-413KH5ZJ73; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-; CHEBI:38545; HSDB 7317
Phase 0: 9
Phase 1: 307
Phase 2: 80
Phase 3: 196
Phase 4: 197
Description:Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt602 446157 Rosuvastatin 3156 HMGCR Homo sapiens (human) None
dt603 446157 Rosuvastatin 3156 HMGCR Homo sapiens (human) 11256847 Competitive
dt604 446157 Rosuvastatin 3156 HMGCR Homo sapiens (human) 11349148 Competitive
dt605 446157 Rosuvastatin 3156 HMGCR Homo sapiens (human) 17574412 Competitive
dt606 446157 Rosuvastatin 3156 HMGCR Homo sapiens (human) 16128575 Competitive
dt607 446157 Rosuvastatin 25675 Hmgcr Rattus norvegicus (Norway rat) 11256847 Competitive
dt608 446157 Rosuvastatin 3949 LDLR Homo sapiens (human) None
dt609 446157 Rosuvastatin 6927 HNF1A Homo sapiens (human) None
dt610 446157 Rosuvastatin 221458 KIF6 Homo sapiens (human) None
dt611 446157 Rosuvastatin 8647 ABCB11 Homo sapiens (human) None

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05912387 Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study EARLY_PHASE1 RECRUITING Stanford University Primary Sclerosing Cholangitis; Inflammatory Bowe… DRUG: Rosuvastatin Details
NCT04883840 Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis PHASE2|PHASE3 RECRUITING Universitaire Ziekenhuizen KU Leuven Ulcerative Colitis DRUG: Rosuvastatin 10mg Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Innovative pH-responsive alginate-coated rosuvastatin-loaded chitosan nanoparti…

PMID: 40606616
Year: 2025
Relationship Type: Treatment Score: 6.5

This study developed and optimized an innovative oral pH-dependent drug delivery system utilizing rosuvastatin-loaded chitosan nanoparticles (RSV-CSN…

Sub-gingival delivery of simvastatin and rosuvastatin for treatment of chronic …

PMID: 36891284
Year: 2023
Relationship Type: Treatment Score: 6.5

BACKGROUND: Statins are lipid-lowering medications that work by blocking rate-limiting enzyme in cholesterol formation. In patients with Chronic peri…

Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of o…

PMID: 28740344
Year: 2017
Relationship Type: Treatment Score: 6.3

AIM: To evaluate the anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium (DSS)…

Protective effect of simvastatin and rosuvastatin on trinitrobenzene sulfonic a…

PMID: 25821305
Year: 2015
Relationship Type: Association Score: 6.3

OBJECTIVE: Statins have anti-inflammatory effects that are not directly related to their cholesterol lowering activity. This study was carried out to…